Gyrolab Resources

Find technical documentation on our products as well as scientific references. 

In some browsers the download of PDFs requires that pop-up is allowed. Please contact maritha.lundin@gyrosproteintech.com if you are not able to view the PDF.

Evaluation of Gyrolab™ and Meso-Scale Discovery platforms in the development of a clinical immunogenicity assay
J Collet, A Moreau et. al. NovImmune SA, Geneva, Switzerland 
[Poster]

Comparative HCP Testing Using Traditional and Emerging Technologies
Martha Jackson, David Cirelli, Phoebe Baldus, Ned Mozier. BioTherapeutics Pharmaceutical Sciences, Analytical Research and Development, Pfizer, Andover, MA 
[Poster]

High Throughput Process-related Impurity Testing Using a Gyrolab™ Workstation
Meletios Roussis, Eric Beard, Keshavamurthy Prakash, Robert Strouse and Michael Washabaugh. Analytical Biochemistry, MedImmune, Gaithersburg, MD 20878 USA 
[Poster]

Gyrolab CHO-HCP kit panel simplifies HCP assay selection in bioprocess development
Gyros Protein Technologies offers a range of five ready-to-use kits to measure HCP impurities from Chinese Hamster Ovary cells (CHO), based on commercially available antibody preparations. 
[Poster]

Development of residual host cell protein assays for recombinant microbial biopharmaceuticals
Katja Peiris and Daniel Schiwek, LCMD Analytical Development, Lonza AG, Switzerland 
[Poster]

Capillary microsampling of liquid matrices. Better Science – Fewer Animals
New opportunities for collection and handling of extremely small volumes of biofluids – From early screen to late clinic. Ove Jonsson Global DMPK, AstraZeneca R&D, Södertälje, Sweden. 
[Poster]

Quantitative Ligand Binding Assay for Determination of Antibody Drug Conjugate Using Gyrolab Immunoassay Platform
Aidong Wu, Tracey Clark, Chad Ray, Frank Barletta, Erick Kindt, Scott Fountain, Pfizer Global R&D, USA 
[Poster]

One mouse one PK The magic of capillary microsampling and the Gyrolab assay platform
Sufyan Maqbool, Jo Goodman, David Fairman, Dominic Corkill, BSU & Bioanalytical Sciences, Clinical Pharmacology & DMPK (CPD) Ove Jonsson, Michael Spreadborough, Christopher Smith. MedImmune 
[Poster]

Development and validation on a pharmacokinetic assay on Gyrolab platform for use in Phase II/III clinical studies
M. Dula, S. Fernando et. al. Morphotek Bioanalytical Dev. 
[Poster]

A Simplified Process to Develop “Fit-for-Purpose” PK/PD Assays in Support of Early Drug Discovery Programs
Rong Liu, Renuka Pillutla, Binodh Desilva, Yan Zhang. BAS-Biologics, Bristol Myers Squibb, Princeton, NJ 
[Poster]

A Generic Pharmacokinetic (PK)/ Toxicokinetic (TK) Assay Kit for Analysis of Biotherapeutic Antibodies in Sera from Several Species for Early-stage Development using Gyrolab™ Platforms
Ready to use Gyrolab Generic PK/TK kits streamlines evaluation of drug candidates for multiple programs using only nanoliter volumes and eliminates the time and resources needed for assay development and reagent screening.  
[Poster]

Product quantification (IgG Titer) using an automated analytical platform–Gyrolab workstation
Lin Wang, Ph.D., Li Zhang, Fang Li and Eike Zimmermann,Ph.D. Boehringer Ingelheim, Fremont CA, USA 
[Poster]